Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Downgraded by BidaskClub
BidaskClub lowered shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) from a buy rating to a hold rating in a research note published on Saturday morning.
Several other research firms have also issued reports on SCMP. Maxim Group set a $23.00 target price on shares of Sucampo Pharmaceuticals and gave the stock a buy rating in a report on Wednesday. Jefferies Group LLC lowered their target price on shares of Sucampo Pharmaceuticals from $13.00 to $11.00 and set a hold rating for the company in a report on Thursday, May 4th. TheStreet lowered shares of Sucampo Pharmaceuticals from a c+ rating to a d rating in a report on Wednesday. Roth Capital set a $30.00 target price on shares of Sucampo Pharmaceuticals and gave the stock a buy rating in a report on Thursday. Finally, ValuEngine lowered shares of Sucampo Pharmaceuticals from a buy rating to a hold rating in a report on Friday, June 2nd. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Sucampo Pharmaceuticals currently has an average rating of Buy and an average price target of $17.63.
Sucampo Pharmaceuticals (SCMP) traded up 0.48% during trading on Friday, hitting $10.40. 469,212 shares of the company’s stock were exchanged. Sucampo Pharmaceuticals has a 52-week low of $9.30 and a 52-week high of $17.55. The firm has a 50 day moving average price of $10.58 and a 200 day moving average price of $10.73. The company’s market cap is $480.42 million.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.22 by $0.06. The firm had revenue of $59.90 million during the quarter, compared to analyst estimates of $56.44 million. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The business’s revenue was up 15.3% on a year-over-year basis. During the same quarter last year, the business earned $0.24 EPS. On average, equities research analysts predict that Sucampo Pharmaceuticals will post $1.02 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Downgraded by BidaskClub” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/08/06/sucampo-pharmaceuticals-inc-nasdaqscmp-downgraded-by-bidaskclub.html.
A number of large investors have recently made changes to their positions in SCMP. Bank of Montreal Can raised its stake in shares of Sucampo Pharmaceuticals by 22.9% in the first quarter. Bank of Montreal Can now owns 24,775 shares of the biopharmaceutical company’s stock worth $272,000 after buying an additional 4,615 shares during the last quarter. State Street Corp raised its stake in shares of Sucampo Pharmaceuticals by 32.9% in the fourth quarter. State Street Corp now owns 581,835 shares of the biopharmaceutical company’s stock worth $7,882,000 after buying an additional 143,906 shares during the last quarter. Virginia Retirement Systems ET AL bought a new stake in shares of Sucampo Pharmaceuticals during the first quarter worth $536,000. Bank of New York Mellon Corp raised its stake in shares of Sucampo Pharmaceuticals by 107.3% in the first quarter. Bank of New York Mellon Corp now owns 367,691 shares of the biopharmaceutical company’s stock worth $4,044,000 after buying an additional 190,292 shares during the last quarter. Finally, Russell Investments Group Ltd. bought a new stake in shares of Sucampo Pharmaceuticals during the fourth quarter worth $555,000. Institutional investors own 55.82% of the company’s stock.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.